In cancer, specific methylation and other alterations of the NFE2L2 promoter have been documented [12,57,58], which can alter the expression levels of NRF2, linked to carcinogenesis through metabolic reprogramming, tumor promotion, inflammation, and resistance to therapy. Here, NFE2L2 is linked to neoplasm.